{
  "docId": "019de516-01ce-701d-bd9b-acac15fa9fab",
  "docSlug": "a13be9775a99db49a0c5c2ac3ee2ea88",
  "documentTitle": "Oculis | Investor Conference Presentation Deck | 39 slides",
  "authorId": "oculis",
  "authorName": "Oculis",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 24,
  "pageCount": 39,
  "prevPage": 23,
  "nextPage": 25,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "overcrowded",
  "nDataPoints": 4,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 0.9,
  "imagePath": null,
  "slideHref": "/slides/019de516-01ce-701d-bd9b-acac15fa9fab/24",
  "deckHref": "/decks/019de516-01ce-701d-bd9b-acac15fa9fab",
  "deckJsonHref": "/decks/019de516-01ce-701d-bd9b-acac15fa9fab.json",
  "deckAnchorHref": "/decks/019de516-01ce-701d-bd9b-acac15fa9fab#slide-24",
  "components": [
    {
      "bbox": {
        "h": 0.11,
        "w": 0.88,
        "x": 0.05,
        "y": 0.563
      },
      "kind": "list",
      "text": "DME Next Steps\nCommencement of Phase 3 Stage 2 studies in 2H 2023\nIf successful, Phase 3 Stage 2 expected to support NDA filing for treatment of DME\nOCS-01 can provide significant value to patients, physicians & payors, if approved",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "061a4d6d-579f-4140-99ce-38b5fd0f6e4f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.11,
        "w": 0.88,
        "x": 0.05,
        "y": 0.379
      },
      "kind": "list",
      "text": "In Phase 3\nPhase 3 Stage 1 in DME: 1º and all 2º endpoints reached, 148 patients\nPhase 2 in Ocular Surgery: Pain and inflammation endpoints reached, 150 patients\nOn-going Phase 3 programs in both indications",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "22f70996-f72e-456f-a8db-88fae7f1896f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.11,
        "w": 0.88,
        "x": 0.05,
        "y": 0.747
      },
      "kind": "list",
      "text": "Ocs-01 Milestones In\nAdditional Indications\nPhase 3 in Ocular Surgery:\nPhase 2 PoC in CME(3):\nOcular Surgery NDA application:\nReadout expected in Q3 2023\nReadout expected in 2H 2024\nApplication in Q4 2024",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b5ca8cf4-cf76-4f17-859e-628342b9caf5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.88,
        "x": 0.05,
        "y": 0.195
      },
      "kind": "list",
      "text": "Transformative Eye Drop\nPotential to be the first topical and non-invasive treatment for DME\nTotal addressable US patient population for DME ~1.2M(1)(2)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fe1b1c60-e6b2-4ca4-a1b6-099e19775464",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.52,
        "x": 0.026,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "(1) ARVO Annual Meeting Abstract, June 2021, Hennings et al. Prognostic determinants of postoperative pseudophakic macular oedema in a tertiary hospital setting.\n(2) Data on file, Skyggn phase 2 study.\n(3) Cystoid Macular Edema (CME).",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cdd9212d-3c3c-4601-8125-80971c659e1a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.704,
        "x": 0.026,
        "y": 0.047
      },
      "kind": "title",
      "text": "OCS-01 | Recap - First Retina Eye Drop for DME",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bdb22a59-0f50-46da-8b1e-7335edabfe77",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "d9d0c277-708b-4f20-a90b-1d7f7feee6e1",
      "evidence": "The slide uses bullet points to present information about the trial, including milestones and next steps.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 24,
      "from": 17,
      "beatId": "47165210-81f8-47ad-ae3f-2582e7380461",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Solution & Approach",
      "beatSlug": "consultants-gambit-solution-approach",
      "evidence": "Slides 17-24 outline OCS-01's potential and the Phase 3 program.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}